Metformin and neoplasia: Implications and indications

Pharmacology and Therapeutics

Volumn 133, Issue 1, 2012, Pages 108-115

  Aljada, Ahmad ^c   Mousa, Shaker A ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

AMPK; Cancer; Cancer stem cell; Chemoprevention; IGF; Keywords; Metastasis; Metformin; mTOR; Rapamycin

Indexed keywords

ADENYLATE KINASE; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; SOMATOMEDIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CLINICAL TRIAL (TOPIC); COLON CANCER; DIABETIC PATIENT; DRUG INDICATION; DRUG MECHANISM; ENDOMETRIUM CANCER; HUMAN; LUNG CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 83555164657     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.09.004     Document Type: Review

References (84)

1. E.Y. Adashi The IGF family and folliculogenesis J Reprod Immunol 39 1998 13 19
2. C. Algire, M. Zakikhani, M.J. Blouin, J.H. Shuai, and M. Pollak Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth Endocr Relat Cancer 15 2008 833 839
3. I.N. Alimova, B. Liu, Z. Fan, S.M. Edgerton, T. Dillon, and S.E. Lind Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro Cell Cycle 8 2009 909 915
4. V.N. Anisimov, L.M. Berstein, P.A. Egormin, T.S. Piskunova, I.G. Popovich, and M.A. Zabezhinski Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice Exp Gerontol 40 2005 685 693
5. V.N. Anisimov, P.A. Egormin, L.M. Bershtein, M.A. Zabezhinskii, T.S. Piskunova, and I.G. Popovich Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice Bull Exp Biol Med 139 2005 721 723
6. I. Ben Sahra, K. Laurent, A. Loubat, S. Giorgetti-Peraldi, P. Colosetti, and P. Auberger The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 27 2008 3576 3586
7. S. Benyoucef, K.H. Surinya, D. Hadaschik, and K. Siddle Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation Biochem J 403 2007 603 613
8. L.M. Bershtein, E.V. Tsyrlina, I.G. Kovalenko, D.A. Vasil'ev, and V.F. Semiglazov Breast cancer receptor status in smoking and diabetic patients Vopr Onkol 51 2005 187 191
9. L.M. Berstein, E.V. Tsyrlina, T.E. Poroshina, V.V. Levina, D.A. Vasilyev, and I.G. Kovalenko Genotoxic factors associated with the development of receptor-negative breast cancer: potential role of the phenomenon of switching of estrogen effects Exp Oncol 28 2006 64 69
10. M. Bodmer, C. Meier, S. Krahenbuhl, S.S. Jick, and C.R. Meier Long-term metformin use is associated with decreased risk of breast cancer Diabetes Care 33 2010 1304 1308
11. S. Bonovas, K. Filioussi, and A. Tsantes Diabetes mellitus and risk of prostate cancer: a meta-analysis Diabetologia 47 2004 1071 1078
12. S.L. Bowker, S.R. Majumdar, P. Veugelers, and J.A. Johnson Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 2006 254 258
13. L.A. Cantrell, C. Zhou, A. Mendivil, K.M. Malloy, P.A. Gehrig, and V.L. Bae-Jump Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy Gynecol Oncol 116 2010 92 98
14. R.T. Chlebowski, E. Aiello, and A. McTiernan Weight loss in breast cancer patient management J Clin Oncol 20 2002 1128 1143
15. C.J. Currie, C.D. Poole, and E.A. Gale The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777
16. A. Czyzyk, and Z. Szczepanik Diabetes mellitus and cancer Eur J Intern Med 11 2000 245 252
17. G.D. Dakubo Mitochondrial Genetics and Cancer 2010 Springer-Verlag Berlin Heidelberg 39 66
18. A.T. De Souza, G.R. Hankins, M.K. Washington, T.C. Orton, and R.L. Jirtle M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity Nat Genet 11 1995 447 449
19. E. Diamanti-Kandarakis, C.D. Christakou, E. Kandaraki, and F.N. Economou Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome Eur J Endocrinol 162 2010 193 212
20. R.J. Dowling, M. Zakikhani, I.G. Fantus, M. Pollak, and N. Sonenberg Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67 2007 10804 10812
21. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
22. J. Everhart, and D. Wright Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis JAMA 273 1995 1605 1609
23. E. Friberg, N. Orsini, C.S. Mantzoros, and A. Wolk Diabetes mellitus and risk of endometrial cancer: A meta-analysis Diabetologia 50 2007 1365 1374
24. A.M. Gonzalez-Angulo, and F. Meric-Bernstam Metformin: a therapeutic opportunity in breast cancer Clin Cancer Res 16 2010 1695 1700
25. P.J. Goodwin, K.I. Pritchard, M. Ennis, M. Clemons, M. Graham, and I.G. Fantus Insulin-lowering effects of metformin in women with early breast cancer Clin Breast Cancer 8 2008 501 505
26. C.A. Granville, N. Warfel, J. Tsurutani, M.C. Hollander, M. Robertson, and S.D. Fox Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors Clin Cancer Res 13 2007 2281 2289
27. V. Grunwald, L. DeGraffenried, D. Russel, W.E. Friedrichs, R.B. Ray, and M. Hidalgo Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells Cancer Res 62 2002 6141 6145
28. E. Guastamacchia, F. Resta, A. Mangia, F. Schittulli, A. Ciampolillo, and V. Triggiani Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets Curr Drug Targets Immune Endocr Metabol Disord 3 2003 205 209
29. S. Hadad, J. Dewar, E. Elseedawy, L. Jordan, C. Purdie, and S. Bray Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial J Clin Oncol Vol. 28 2010 560 (Suppl)
30. D.G. Hardie Neither LKB1 nor AMPK are the direct targets of metformin Gastroenterology 131 2006 973 author reply 974-975.
31. S.A. Hawley, A.E. Gadalla, G.S. Olsen, and D.G. Hardie The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism Diabetes 51 2002 2420 2425
32. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945
33. S. Hernandez-Diaz, and H.O. Adami Diabetes therapy and cancer risk: causal effects and other plausible explanations Diabetologia 53 2010 802 808
34. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, and K. Struhl Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res 69 2009 7507 7511
35. K. Hosono, H. Endo, H. Takahashi, M. Sugiyama, E. Sakai, and T. Uchiyama Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev Res (Phila) 3 2010 1077 1083
36. K. Hosono, H. Endo, H. Takahashi, M. Sugiyama, T. Uchiyama, and K. Suzuki Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase Mol Carcinog 49 2010 662 671
37. L. Ibanez, K. Ong, C. Valls, M.V. Marcos, D.B. Dunger, and F. de Zegher Metformin treatment to prevent early puberty in girls with precocious pubarche J Clin Endocrinol Metab 91 2006 2888 2891
38. K. Inoki, M.N. Corradetti, and K.L. Guan Dysregulation of the TSC-mTOR pathway in human disease Nat Genet 37 2005 19 24
39. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
40. S. Jiralerspong, S.L. Palla, S.H. Giordano, F. Meric-Bernstam, C. Liedtke, and C.M. Barnett Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer J Clin Oncol 27 2009 3297 3302
41. J.S. Kasper, and E. Giovannucci A meta-analysis of diabetes mellitus and the risk of prostate cancer Cancer Epidemiol Biomarkers Prev 15 2006 2056 2062
42. J. Kotzka, and D. Muller-Wieland Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin Ther Targets 8 2004 141 149
43. G.W. Landman, N. Kleefstra, K.J. van Hateren, K.H. Groenier, R.O. Gans, and H.J. Bilo Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 Diabetes Care 33 2010 322 326
44. S.C. Larsson, L. Bergkvist, and A. Wolk Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women Int J Cancer 125 2009 153 157
45. S.C. Larsson, C.S. Mantzoros, and A. Wolk Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 2007 856 862
46. S.C. Larsson, N. Orsini, K. Brismar, and A. Wolk Diabetes mellitus and risk of bladder cancer: a meta-analysis Diabetologia 49 2006 2819 2823
47. S.C. Larsson, N. Orsini, and A. Wolk Diabetes mellitus and risk of colorectal cancer: a meta-analysis J Natl Cancer Inst 97 2005 1679 1687
48. D. Li, S.C. Yeung, M.M. Hassan, M. Konopleva, and J.L. Abbruzzese Antidiabetic therapies affect risk of pancreatic cancer Gastroenterology 137 2009 482 488
49. X. Li, N. Zhang, Y. Li, Y. Shi, D. Li, and Y. Xie Effects of metformin and rosiglitazone on peripheral insulin resistance and beta-cell function in obesity: a double-blind, randomized, controlled study J Int Med Res 39 2011 358 365
50. G. Libby, L.A. Donnelly, P.T. Donnan, D.R. Alessi, A.D. Morris, and J.M. Evans New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
51. B. Liu, Z. Fan, S.M. Edgerton, X.S. Deng, I.N. Alimova, and S.E. Lind Metformin induces unique biological and molecular responses in triple negative breast cancer cells Cell Cycle 8 2009 2031 2040
52. J.M. Lord, I.H. Flight, and R.J. Norman Metformin in polycystic ovary syndrome: systematic review and meta-analysis BMJ 327 2003 951 953
53. G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, M. Zoli, and N. Melchionda Metformin in non-alcoholic steatohepatitis Lancet 358 2001 893 894
54. B. Martin-Castillo, J. Dorca, A. Vazquez-Martin, C. Oliveras-Ferraros, E. Lopez-Bonet, and M. Garcia Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology Ann Oncol 21 2010 187 189
55. R.M. Memmott, J.R. Mercado, C.R. Maier, S. Kawabata, S.D. Fox, and P.A. Dennis Metformin prevents tobacco carcinogen-induced lung tumorigenesis Cancer Prev Res (Phila) 3 2010 1066 1076
56. P. Muti, F. Berrino, V. Krogh, A. Villarini, M. Barba, and S. Strano Metformin, diet and breast cancer: an avenue for chemoprevention Cell Cycle 8 2009 2661
57. S. Niraula, V. Stambolic, R. Dowling, M. Ennis, M. Chang, and S. Done Clinical and biologic effects of metformin in early stage breast cancer Abstract # PD03-06 Cancer Res Vol. 70 2010 24,Suppl 104S
58. P. Pasanisi, F. Berrino, M. De Petris, E. Venturelli, A. Mastroianni, and S. Panico Metabolic syndrome as a prognostic factor for breast cancer recurrences Int J Cancer 119 2006 236 238
59. T. Patel, G. Hruby, K. Badani, C. Abate-Shen, and J.M. McKiernan Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin Urology 76 2010 1240 1244
60. A.C. Patel, N.P. Nunez, S.N. Perkins, J.C. Barrett, and S.D. Hursting Effects of energy balance on cancer in genetically altered mice J Nutr 134 2004 3394S 3398S
61. L. Pawelczyk, R.Z. Spaczynski, B. Banaszewska, and A.J. Duleba Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome Eur J Obstet Gynecol Reprod Biol 113 2004 209 213
62. K.N. Phoenix, F. Vumbaca, and K.P. Claffey Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model Breast Cancer Res Treat 113 2009 101 111
63. K. Sakamoto, A. McCarthy, D. Smith, K.A. Green, D. Grahame Hardie, and A. Ashworth Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction EMBO J 24 2005 1810 1820
64. R.J. Shaw, K.A. Lamia, D. Vasquez, S.H. Koo, N. Bardeesy, and R.A. Depinho The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 310 2005 1642 1646
65. Y. Shi, J. Gera, L. Hu, J.H. Hsu, R. Bookstein, and W. Li Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res 62 2002 5027 5034
66. S.Y. Shieh, M. Ikeda, Y. Taya, and C. Prives DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2 Cell 91 1997 325 334
67. H.D. Strickler, J. Wylie-Rosett, T. Rohan, D.R. Hoover, S. Smoller, and R.D. Burk The relation of type 2 diabetes and cancer Diabetes Technol Ther 3 2001 263 274
68. B.K. Tan, R. Adya, J. Chen, H. Lehnert, L.J. Sant Cassia, and H.S. Randeva Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells J Clin Endocrinol Metab 96 2011 808 816
69. A. Tomimoto, H. Endo, M. Sugiyama, T. Fujisawa, K. Hosono, and H. Takahashi Metformin suppresses intestinal polyp growth in ApcMin/+ mice Cancer Sci 99 2008 2136 2141
70. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Cufi, S. del Barco, B. Martin-Castillo, and E. Lopez-Bonet The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells Oncol Rep 25 2011 135 140
71. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Cufi, S. del Barco, B. Martin-Castillo, and J.A. Menendez Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status Cell Cycle 9 2010 3807 3814
72. A. Vazquez-Martin, C. Oliveras-Ferraros, S. del Barco, B. Martin-Castillo, and J.A. Menendez The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy Ann Oncol 20 2009 592 595
73. A. Vazquez-Martin, C. Oliveras-Ferraros, S. del Barco, B. Martin-Castillo, and J.A. Menendez mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb) Clin Transl Oncol 11 2009 455 459
74. A. Vazquez-Martin, C. Oliveras-Ferraros, S. del Barco, B. Martin-Castillo, and J.A. Menendez The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Breast Cancer Res Treat 126 2011 355 364
75. A. Vazquez-Martin, C. Oliveras-Ferraros, and J.A. Menendez The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells Cell Cycle 8 2009 88 96
76. O. Warburg On the origin of cancer cells Science 123 1956 309 314
77. G.S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G.W. Krystal The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy Clin Cancer Res 11 2005 1563 1571
78. I. Wolf, S. Sadetzki, R. Catane, A. Karasik, and B. Kaufman Diabetes mellitus and breast cancer Lancet Oncol 6 2005 103 111
79. J.L. Wright, and J.L. Stanford Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes Control 20 2009 1617 1622
80. S. Yakar, N.P. Nunez, P. Pennisi, P. Brodt, H. Sun, and L. Fallavollita Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones Endocrinology 147 2006 5826 5834
81. M. Zakikhani, R. Dowling, I.G. Fantus, N. Sonenberg, and M. Pollak Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 2006 10269 10273
82. M. Zakikhani, R.J. Dowling, N. Sonenberg, and M.N. Pollak The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase Cancer Prev Res (Phila) 1 2008 369 375
83. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, and J. Fenyk-Melody Role of AMP-activated protein kinase in mechanism of metformin action J Clin Investig 108 2001 1167 1174
84. Y. Zhuang, and W.K. Miskimins Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1 J Mol Signal 3 2008 18